Key Highlights

  • Novavax (NASDAQ:NVAX) closed at USD 12.75 in the October 9, 2026 session, up USD 1.74 or 15.8%, and it appears in published market data among names with high short interest positions.
  • Volume was 6.199M shares against a three-month average of 5.159M, about 1.2 times, simple arithmetic on two published numbers, so the jump came without an extreme surge in trading activity.
  • The 52-week range runs from USD 6.20 to USD 13.39, so the price is about 5% below the high and roughly double the low, and the market capitalization is 1.816B.
  • No company-specific catalyst was identified for the 15.8% move in Novavax (NASDAQ:NVAX) on October 9, 2026; earlier gains on October 5, 2026 also had no catalyst identified, so the pattern reflects published market data.

The Move in Numbers

Novavax (NASDAQ:NVAX), a protein-based vaccine maker with a Sanofi partnership, rose USD 1.74 to USD 12.75 in the October 9, 2026 session. Working back from the published change, the prior close was about USD 11.01. Volume of 6.199M shares was about 1.2 times the three-month average of 5.159M, which is simple arithmetic on two published numbers. A gain of 15.8% on near-average volume is unusual and suggests that a limited number of buyers was enough to move the price. Earlier, on October 5, 2026, shares rose about 10.5% to about USD 11.56, again with no catalyst identified. No price to earnings ratio is published, because the company is not reporting steady profit.

Short Interest and the Squeeze Mechanism

When many shares are sold short, a rise forces some sellers to buy back to limit losses, and that buying pushes the price up further. This feedback loop is called a short squeeze, and it can lift a stock sharply without any news. Published market data lists Novavax (NASDAQ:NVAX) among names with high short interest positions, but it gives no figure, and it does not show that covering caused this rise. Two sharp gains within a week fit the squeeze pattern, yet fit other explanations equally well, including rumors, positioning ahead of events or thin liquidity. The data alone cannot distinguish between those explanations, so readers should treat any single story with caution.

Fundamentals Behind the Volatility

Revenue for the quarter reported on August 6, 2026 was USD 56.7 million, down 76.2% from a year earlier, and the adjusted loss per share was USD 0.32 against USD 0.38 expected. Vaccine makers depend on seasonal demand, partner milestones and regulatory decisions, so results swing widely. The price now sits about 5% below the 52-week high of USD 13.39 and roughly double the low of USD 6.20, so recent gains have been large. The S&P 500 closed at 7,811.5, just below its record, and the Consumer Price Index report on October 14 at 8:30 a.m. ET may move rate expectations for biotech shares, which are sensitive to funding costs.

Where Things Stand

The answer to why Novavax (NASDAQ:NVAX) surged 15.8% in one session is that no company-specific catalyst was identified. The rise to USD 12.75 came on volume about 1.2 times average, with a similar unexplained gain of about 10.5% on October 5, 2026. High short interest can magnify buying when shorts cover, but published market data does not prove that happened. Results reported on August 6, 2026 showed revenue down 76.2%, so volatility is high. The next markers are bank earnings on October 13 and the CPI report on October 14.